Latest Pharma and Biotech News
Pharmaceutical
15 May 2025 US Department of Health and Human Services (HHS) Secretary Robert F Kennedy Jr (RFK Jr) has spoken in defence of his proposed HHS budget for fiscal year 2026 to the Senate Health, Education, Labor, and Pensions (HELP) Committee.
Today's issue
Refine Search
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Pharmaceutical
USA-based Inozyme Pharma, a biopharma developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, has a new chief medical officer (CMO). 15 May 2025
Biotechnology
New Jersey, USA-based cancer giant Merck & Co has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago. 15 May 2025
Biotechnology
US pharma giant Merck & Co today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. 15 May 2025
Biotechnology
The integration of genomics into the pharmaceutical industry has allowed researchers to better understand the genetic factors underlying diseases, leading to the development of more targeted and effective therapies. 15 May 2025
Pharmaceutical
In a world where western firms increasingly seek to ingratiate themselves with Middle Eastern leaders and investors, a Saudi company has sought to curry favor with US President Donald Trump in an announcement on pharma manufacturing. 15 May 2025
Biotechnology
Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the US Food and Drug Administration (FDA), said the drug’s developer, AbbVie. 15 May 2025
Pharmaceutical
London-based specialty pharmaceutical company CNX Therapeutics is set to fast-track its European growth strategy after being chosen as one of four portfolio companies for Inflexion’s new Continuation Fund, which closed at £2.3 billion ($3 billion). The fund, the largest of its kind raised in Europe to date, aims to support high-performing businesses with significant growth potential. 15 May 2025
Biotechnology
Swedish biotech firm PeptiSystems has joined forces with Asahi Kasei Bioprocess America in a global partnership set to reshape how peptide drugs are made. 15 May 2025
Pharmaceutical
German science and technology company Merck (MRK: DE) reported a solid start to 2025, with group net sales rising 2.5% organically to 5.3 billion euros ($5.7 billion) in the first quarter. 15 May 2025
Pharmaceutical
Aiming to expand its hepatology portfolio, UK pharma major GSK yesterday announced that it has entered into an agreement to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. 15 May 2025
Pharmaceutical
US Department of Health and Human Services (HHS) Secretary Robert F Kennedy Jr (RFK Jr) has spoken in defence of his proposed HHS budget for fiscal year 2026 to the Senate Health, Education, Labor, and Pensions (HELP) Committee. 15 May 2025
Pharmaceutical
Marking the latest move to pledge to spend billions of dollars into the USA, French pharm major Sanofi (Euronext: SAN) announced its intention to invest at least $20 billion in the country through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing. 15 May 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma today released financial results for the first-quarter of 2025, noting its continued robust growth, driven by dermatology, and made significant strategic progress. 15 May 2025
Pharmaceutical
German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI, aiming to accelerate the development of new cancer therapies by harnessing real-world data and artificial intelligence. 15 May 2025
Biotechnology
Japanese pharma major Takeda announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Vonvendi [von Willebrand factor (Recombinant)] for investigational routine prophylactic use in adults (age 18 years and older) with von Willebrand disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative use in children with VWD. 15 May 2025
Pharmaceutical
The US Food and Drug Administration approved Welireg (belzutifan), from US pharma giant Merck & Co, for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). 15 May 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has obtained regulatory approval from the domestic regulator for Elevidys Intravenous Infusion (delandistrogene moxeparvovec) as a regenerative medicine product for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway. 15 May 2025
Pharmaceutical
US analytics specialist Phesi has called for a major rethink in how oncology trials are planned and run, saying clinical development has failed to keep pace with scientific progress. 15 May 2025
Pharmaceutical
US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 14 May 2025
All news
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Pharmaceutical
USA-based Inozyme Pharma, a biopharma developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, has a new chief medical officer (CMO). 15 May 2025
Biotechnology
New Jersey, USA-based cancer giant Merck & Co has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago. 15 May 2025
Biotechnology
US pharma giant Merck & Co today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. 15 May 2025
Biotechnology
The integration of genomics into the pharmaceutical industry has allowed researchers to better understand the genetic factors underlying diseases, leading to the development of more targeted and effective therapies. 15 May 2025
Pharmaceutical
In a world where western firms increasingly seek to ingratiate themselves with Middle Eastern leaders and investors, a Saudi company has sought to curry favor with US President Donald Trump in an announcement on pharma manufacturing. 15 May 2025
Biotechnology
Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the US Food and Drug Administration (FDA), said the drug’s developer, AbbVie. 15 May 2025
Pharmaceutical
London-based specialty pharmaceutical company CNX Therapeutics is set to fast-track its European growth strategy after being chosen as one of four portfolio companies for Inflexion’s new Continuation Fund, which closed at £2.3 billion ($3 billion). The fund, the largest of its kind raised in Europe to date, aims to support high-performing businesses with significant growth potential. 15 May 2025
Biotechnology
Swedish biotech firm PeptiSystems has joined forces with Asahi Kasei Bioprocess America in a global partnership set to reshape how peptide drugs are made. 15 May 2025
Pharmaceutical
German science and technology company Merck (MRK: DE) reported a solid start to 2025, with group net sales rising 2.5% organically to 5.3 billion euros ($5.7 billion) in the first quarter. 15 May 2025
Pharmaceutical
Aiming to expand its hepatology portfolio, UK pharma major GSK yesterday announced that it has entered into an agreement to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. 15 May 2025
Pharmaceutical
US Department of Health and Human Services (HHS) Secretary Robert F Kennedy Jr (RFK Jr) has spoken in defence of his proposed HHS budget for fiscal year 2026 to the Senate Health, Education, Labor, and Pensions (HELP) Committee. 15 May 2025
Pharmaceutical
Marking the latest move to pledge to spend billions of dollars into the USA, French pharm major Sanofi (Euronext: SAN) announced its intention to invest at least $20 billion in the country through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing. 15 May 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma today released financial results for the first-quarter of 2025, noting its continued robust growth, driven by dermatology, and made significant strategic progress. 15 May 2025
Pharmaceutical
German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI, aiming to accelerate the development of new cancer therapies by harnessing real-world data and artificial intelligence. 15 May 2025
Biotechnology
Japanese pharma major Takeda announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Vonvendi [von Willebrand factor (Recombinant)] for investigational routine prophylactic use in adults (age 18 years and older) with von Willebrand disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative use in children with VWD. 15 May 2025
Pharmaceutical
The US Food and Drug Administration approved Welireg (belzutifan), from US pharma giant Merck & Co, for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). 15 May 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has obtained regulatory approval from the domestic regulator for Elevidys Intravenous Infusion (delandistrogene moxeparvovec) as a regenerative medicine product for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway. 15 May 2025
Pharmaceutical
US analytics specialist Phesi has called for a major rethink in how oncology trials are planned and run, saying clinical development has failed to keep pace with scientific progress. 15 May 2025
Pharmaceutical
US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 14 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze